title: Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3).
abstract: We characterized the electrophysiology, kinetics, and quantitative structure-activity relationship (QSAR) of the human concentrative nucleoside transporter 3 (hCNT3) expressed in Xenopus laevis oocytes by measuring substrate-induced inward currents using a two-microelectrode voltage-clamp system. At membrane potentials between -30 and -150 mV, sodium activation of gemcitabine transport was sigmoidal, with a K0.5 of 8.5+/-0.3 mM for Na+ and a Hill coefficient of 2.2+/-0.25 independent of membrane potential. We measured the Imax and K0.5 for substrate at -50 mV for the nucleoside analog drugs gemcitabine (638+/-58 nA, 59.7+/-17.5 microM), ribavirin (546+/-37 nA, 61.0+/-13.2 microM), AZT (420+/-4 nA, 310+/-9 microM), and 3-deazauridine (506+/-30 nA, 50.8+/-9.90 microM). K0.5 and Imax for substrate were dependent on membrane potential (both increasing as the membrane became more hyperpolarized) for all four drugs. hCNT3 also exhibited pre-steady-state currents. The quantitative structure-activity relationship (QSAR) was examined using comparative molecular field analysis and comparative molecular similarity indices analysis of the inward currents induced by 27 nucleoside analogs with substitutions at both the ribose and the nucleobase. Two statistically significant QSAR models identified electrostatic interaction as the major force in hCNT3 transport and attributed a critical role to the 3'-hydroxyl position of hCNT3 substrates. Steric hindrance at the 3-position and positive charge at the 5-position of the pyrimidine ring were favorable for transport. Two hCNT3 pharmacophore models revealed the minimal features required for hCNT3 transport as two hydrogen bond acceptors at 3'-OH and 5'-O and the hydrophobic center occupied by the base ring.
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, USA.
authors.forename: Huankai
authors.initials: H
authors.lastname: Hu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Endres
authors.forename: Cheng
authors.initials: C
authors.lastname: Chang
authors.forename: Nagavedi S
authors.initials: NS
authors.lastname: Umapathy
authors.forename: Eun-Woo
authors.initials: EW
authors.lastname: Lee
authors.forename: You-Jun
authors.initials: YJ
authors.lastname: Fei
authors.forename: Shirou
authors.initials: S
authors.lastname: Itagaki
authors.forename: Peter W
authors.initials: PW
authors.lastname: Swaan
authors.forename: Vadivel
authors.initials: V
authors.lastname: Ganapathy
authors.forename: Jashvant D
authors.initials: JD
authors.lastname: Unadkat
mesh_terms: D000465:Algorithms; D000818:Animals; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004594:Electrophysiology / Q000379:methods; D005260:Female; D006801:Humans; D007700:Kinetics; D008564:Membrane Potentials / Q000502:physiology; D026901:Membrane Transport Proteins / Q000737:chemistry* / Q000502:physiology*; D009705:Nucleosides / Q000737:chemistry / Q000378:metabolism; D009865:Oocytes / Q000502:physiology; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship; D014162:Transfection; D014982:Xenopus laevis; D000093542:Gemcitabine
chemical_list: D026901:Membrane Transport Proteins; D009705:Nucleosides; D011687:Purines; D011743:Pyrimidines; C065171:cif nucleoside transporter; D003841:Deoxycytidine; D000093542:Gemcitabine